Fig. 3From: Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processesComparison of SMC and NICE recommendations for EOL designation and access a. Comparison of EOL designation: number of submissions considered for granting of EOL/rare status by SMC (blue) and NICE (red), and level of agreement where both agencies gave a designation b. Comparison of access to drugs: number of drugs funded in Scotland (blue) and England (red), via SMC, NICE and CDF decisionsBack to article page